Diarrhea News and Research

Latest Diarrhea News and Research

New Kaiser Family Foundation tool shows which global health interventions are working

New Kaiser Family Foundation tool shows which global health interventions are working

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

E. coli bacterial research articles now available for free on SpringerLink

E. coli bacterial research articles now available for free on SpringerLink

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Scientists find increases in rain and temperature could signal deadly cholera outbreaks months before they strike

Scientists find increases in rain and temperature could signal deadly cholera outbreaks months before they strike

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Complementary technologies for rapid EHEC identification and detection

Complementary technologies for rapid EHEC identification and detection

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

WGO to focus on diarrheal disease prevention, management during World Digestive Health Day

New book on 'Overcoming Anxiety, Worry, and Fear'

New book on 'Overcoming Anxiety, Worry, and Fear'

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

Probiotic bacterial protein could offer new oral therapeutic option for inflammatory bowel disorders

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

Journal of Clinical Oncology publishes Exelixis' cabozantinib phase 1 trial results in lymphoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.